PRKN and Parkinson disease: According to our results, an impressive observation regarding treatment requirements is that a proportion of PD patients (3/13) carrying PRKN mutations had an excellent response to dopamine agonists and had not been started on L-Dopa therapy even after 20 years since disease onset.